MedSci Healthcare Announces Strategic Investment in AI Medical Science Inc. (AIMS) to Accelerate Generative Medical AI Development

MedSci Healthcare Holdings Limited (Stock Code: 2415.HK, "MedSci Healthcare"), a global leader in professional digital medical services, today announced the completion of a strategic investment in AI Medical Science Inc. ("AIMS"), a pioneering R&D institution focused on medical artificial intelligence.

The investment, totaling nearly USD 1 million, is earmarked for AIMS’s advanced research in Generative AI (AIGC), medical-specific Large Language Models (LLMs), and Multi-Agent collaborative architectures. The funding aims to drive digital efficiency in medical academic communication and scientific output through cutting-edge technological empowerment.

AIMS is dedicated to continuously improving healthcare quality through algorithm-driven innovations. Its primary R&D focuses include the Clinical Research Insight Platform for research design, the Clinical Decision Platform System for intelligent assessment and decision-making, and specialized digital interaction tools for the global market. With this strategic capital infusion, AIMS will accelerate its technological iterations and service deployment across North America and beyond.

"In 2026, AI has transitioned from technical preparation to a phase of comprehensive value creation," said Dr. Zhang Fabao, Chairman of MedSci Healthcare. "The forward-looking technical architecture of AIMS aligns perfectly with our global vision. Through this strategic funding, we are supporting their independent innovation in medical AIGC to build a global ecosystem driven by evidence-based intelligence."

This strategic move is a key component of MedSci Healthcare’s "AI Empowerment" strategy and highlights the Group’s commitment to identifying and nurturing high-potential medical technology ventures worldwide.